RudaCure Inc. (PDG Yongho Kim), une bioventure spécialisée dans le développement de médicaments contre la douleur, a été sélectionnée comme newly certified '2025 Hi-Seoul Enterprise' by the Ville métropolitaine de Séoul and Seoul Business Agency (SBA).
The Hi-Seoul Enterprise certification is a program where Ville métropolitaine de Séoul completly evaluates potentiel de croissance, profitability, and global capabilities to select and support prometteur SMEs in the region. Grâce à cela certification, RudaCure has officially been recognized for its développement de médicaments technology and business achievements.
In 2024, the average revenue of Hi-Seoul certified companies reached KRW 14.5 billion, with approximately 50% of certified companies expanding into 127 countries, generating annual exports of KRW 3.5 trillion. Actuellement, a total of 1,259 companies hold this certification, and certified companies enjoy divers benefits notamment preferential selection for SBA-operated programs, marketing and overseas expansion support, and tax and financial advantages.
RudaCure's traitement de la sécheresse oculaire RCI001 has récemment obtained U.S. FDA essai clinique de Phase 2 IND approval, signaling the beginning of de l'entreprise advancement into the marché mondial. These results have validated de l'entreprise potential and capabilities, demonstrating synergy with the Hi-Seoul Enterprise certification and establishing a strong foundation for growth.
le PDG Yongho Kim of RudaCure a déclaré : "The Hi-Seoul Enterprise certification is meaningful as official recognition of RudaCure's innovant technology and potentiel de croissance in développement de nouveaux médicaments. We will leverage this momentum to secure global compétitivité and lead the thérapeutiques de la douleur market through the development of innovant treatments."